NAME	MARKET CAP	FORWARD PE RATIO
Tempus AI, Inc. (TEM)	$10.73B	N/A
Insulet Corp. (PODD)vs ›	$10.96B	24.29
Walgreens Boots Alliance, Inc. (WBA)vs ›	$10.37B	7.65
Bio-Techne Corporation (TECH)vs ›	$11.14B	36.89
Charles River Laboratories International, Inc. (CRL)vs ›	$11.25B	20.18
Baxter International Inc. (BAX)vs ›	$11.60B	11.45
Universal Health Services, Inc. (UHS)vs ›	$9.72B	6.66
Henry Schein, Inc. (HSIC)vs ›	$9.55B	15.56
Molina Healthcare, Inc. (MOH)vs ›	$12.09B	45.00
Revvity, Inc. (RVTY)vs ›	$12.60B	20.86

Trailing vs Forward

Trailing P/E

N/A

reported TTM EPS

Forward P/E

N/A

consensus next-FY EPS

Forward P/E by Fiscal Year

View All Analyst Estimates

At today's $61.50 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.

Fiscal year end	Consensus EPS	Estimate range	Analysts	Implied P/E
2026-12-31	$-0.36	$-0.56 – $-0.18	10	n/m
2027-12-31	$-0.08	$-0.64 – $0.60	10	n/m
2028-12-31	$0.66	$-0.10 – $1.23	8	93.0x

Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

About Tempus AI, Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

Chicago, IL

3,800 employees

www.tempus.com

Healthcare / Medical - Healthcare Information Services